Healius (HLS) AGM 2025 summary

Opening remarks and agenda

• Chair welcomed attendees, acknowledged traditional land owners, and introduced the Board and management team.

• Outlined contingency plans for technical issues and confirmed meeting quorum.

• Agenda included Chair and CEO addresses, Q&A, and formal business with voting procedures explained.

Financial performance review

• Sale of Lumus Imaging for AUD 965 million enabled full debt repayment and a special dividend of nearly AUD 300 million.

• Group revenue for Q1 FY 2026 increased by 4.2%, with pathology revenue up 3.9% and Agilex Biolabs up 13.8%.

• Committed to AUD 15–20 million in annualized support cost savings, with AUD 7.3 million achieved in FY 2025 and AUD 8.5 million planned for FY 2026.

• Labor costs expected to remain broadly flat year-on-year; cash position expected to improve.

Board and executive committee updates

• Four new Non-Executive Directors appointed in the past year, with ongoing focus on board refreshment and skills balance.

• CFO transition from Steve Humphries to Andrew Thomson, with a smooth handover underway.

• Board confident in directors' ability to manage responsibilities and committed to ongoing succession planning.